GlassScriptPhysician profile
Ahmed Ouni
NPI 1184158867
$33,423.18
in general payments reported to CMS, 2019-2025
21 companies · $1,527 in 2025
The $1,527 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $280 · 2023: $15K · 2024: $17K · 2025: $1,527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $25K · Food and Beverage: $4,083 · Travel and Lodging: $4,060.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $25,000.00 |
| Food and Beverage | $4,082.68 |
| Travel and Lodging | $4,060.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $29,873.40 | 2023-2025 | Resolution 360 Clip, Apollo Esg Nxt System, Orise |
| Olympus Corporation of The Americas | $1,207.54 | 2023-2024 | Visiglide, Disposable Distal Attachment |
| Madrigal Pharmaceuticals | $528.01 | 2025 | Rezdiffra |
| Conmed Corporation | $361.62 | 2024-2025 | Conmed Generators, Conmed Biliary, Conmed Dilation |
| Abbvie INC. | $357.88 | 2024-2025 | |
| Gilead Sciences, INC. | $203.14 | 2024-2025 | |
| Axonics, INC. | $162.67 | 2024 | Axonics |
| Cook Medical LLC | $140.33 | 2021 | |
| Wilson Cook Medical Incorporated | $140.15 | 2021 | |
| Novo Nordisk INC | $95.05 | 2025 | |
| Merit Medical Systems INC | $71.35 | 2024 | Esophyx |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.89 | 2024-2025 | Xifaxan |
| Qol Medical, LLC | $49.13 | 2024 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $36.74 | 2024 | Dupixent |
| Pfizer INC. | $25.64 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $23.25 | 2024 | Zeposia |
| Braintree Laboratories, INC. | $21.48 | 2024 | Sutab, Suflave |
| Lilly USA, LLC | $19.43 | 2025 | Omvoh |
| Enterra Medical, INC. | $16.95 | 2025 | |
| Capsovision, INC. | $16.27 | 2024 | Capsocam Plus |
| Medtronic, INC. | $15.26 | 2024 | Bravo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Ouni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.